跳至主要内容
临床试验/NL-OMON52960
NL-OMON52960已完成不适用

A Study of Disease Progression in Genetically Defined Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration - GTSCOPE study

Gyroscope Therapeutics Limited0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • Inclusion Criteria:, 1. Aged >=18 years, 2. Able and willing to give consent to
  • study participation, 3. Presence of unilateral or bilateral GA due to AMD, 4.
  • The GA lesion in at least one eye must reside completely within the FAF image,
  • 5. For Group 1, subjects will be required to have a serum CFI level below the
  • lower limit of the assay together with a
  • rare genetic variant of the CFI gene OR for Group 2, subjects will have a
  • genetic variant of a complement factor
  • gene and do not qualify for Group 1, 6. Able to attend all study visits and
  • complete the study procedures, 7. BCVA of 40 letters or better using ETDRS
  • charts in the eye that meets inclusion criterion 3

排除标准

  • Exclusion Criteria:, 1. Evidence or history of neovascular AMD or diabetic
  • retinopathy; previous intravitreal drug delivery
  • [either eye] received within 4 weeks or 5 half-lives whichever is longer,
  • before screening/baseline visit, 2. Any other significant ocular or non-ocular
  • disease/disorder which, in the opinion of the investigator,
  • may influence the results of the study, or the subject*s ability to
  • participate in the study, 3. Participation in another research study involving
  • an investigational product within the previous 4 weeks
  • or 5 half-lives whichever is longer, from the screening/baseline visit OR
  • received a gene/cell therapy at
  • any time previously

研究者

相似试验